title: [InoPro trial: collaboration between urologists and primary care physicians in the treatment of osteoporosis in prostate cancer patients].
abstract: BACKGROUND
  Osteoporosis is more common in elderly men than previously suspected. Prostate cancer patients may have an increased rate of osteopenia and osteoporosis independent of therapy. Osteopenia and fracture risk are accelerated in men receiving androgen deprivation therapy. Nevertheless, little is done by primary care physicians and urologists to diagnose and treat osteoporosis in men.
  
  
  OBJECTIVE
  (1) Assess prostate cancer patients' compliance and adherence to bisphosphonate therapy; (2) Increase awareness for osteoporosis in men diagnosed with prostate cancer among urologists and primary care physicians and to evaluate collaboration between the two disciplines.
  
  
  METHODS
  We included patients with confirmed diagnosis of prostate cancer who fulfilled one or more of the following criteria: (1) age 70 and above; (2) age 60 and above with androgen deprivation therapy or (3) prior diagnosis of osteopenia and osteoporosis. Qualified patients were referred to DXA bone density test. Patients with osteopenia or osteoporosis, who were naïve to bisphosphonates, received recommendations for oral bisphosphonates. Follow-up lasted 6 months and included 2 office visits to ensure patients' compliance and adherence to recommended therapy.
  
  
  RESULTS
  A total of 28 community-based urologists recruited 180 patients. Of the 180 prostate cancer patients, 87 (48%) had osteoporosis and 93 (52%) osteopenia, all were naïve to bisphosphonates. Of the 180 patients, 153 (85%) patients started treatment with bisphosphonates after inclusion; 147/180 (82%) and 136/180 (76%) patients stayed on bisphosphonates for 3 and 6 months respectively. Primary care physicians adopted recommendations for bisphosphonate in 123/180 (68%).
  
  
  CONCLUSIONS
  This study showed high compliance and adherence of prostate cancer patients for bisphosphonate recommendation.
authors.forename: Menachem
authors.initials: M
authors.lastname: Laufer
authors.forename: Thomas
authors.initials: T
authors.lastname: Keller
authors.forename: Vladimir
authors.initials: V
authors.lastname: Gershman
authors.forename: Zvi
authors.initials: Z
authors.lastname: Ferman
authors.forename: Miriam
authors.initials: M
authors.lastname: Sarid
authors.forename: Ilan
authors.initials: I
authors.lastname: Leibovitch
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D003299:Cooperative Behavior; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D010820:Physicians / Q000458:organization & administration; D058007:Physicians, Primary Care / Q000458:organization & administration; D011471:Prostatic Neoplasms / Q000150:complications* / Q000473:pathology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates